[go: up one dir, main page]

GB1246639A - Dehydroepiandrosterone esters - Google Patents

Dehydroepiandrosterone esters

Info

Publication number
GB1246639A
GB1246639A GB4629968A GB4629968A GB1246639A GB 1246639 A GB1246639 A GB 1246639A GB 4629968 A GB4629968 A GB 4629968A GB 4629968 A GB4629968 A GB 4629968A GB 1246639 A GB1246639 A GB 1246639A
Authority
GB
United Kingdom
Prior art keywords
oestrogen
preparations
esters
complaints
preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4629968A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of GB1246639A publication Critical patent/GB1246639A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

1,246,639. Medicines comprising steroids. SCHERING A.G. 30 Sept., 1968 [4 Oct., 1967], No. 46299/68. Heading A5B. [Also in Division C2] Pharmaceutical preparations, suitable for the treatment of climacteric complaints, osteoporosis, deafness due to old age, blood perfusion complaints, heart diseases and depressive states, comprise novel esters of 3 #-hydroxy-#<SP>5</SP>-androsten-17-one with C 7-14 aliphatic carboxylic acids and suitable carriers and/or an oestrogen. Preferred esters are the oenanthate and undecylenate and a preferred oestrogen is oestradiol 17-valerate. Dosage units generally contain 50-500 mg., preferably 100-300 mg., of the ester, and 0.5-10, preferably about 4; mg. of the oestrogen. The preparations are normally in a form suitable for intramuscular infection e.g. oily solutions such as in sesame or castor oil; diluents and/or solubilizing agents e.g. benzyl benzoate, may also be added. Preparations for oral administration are also referred to.
GB4629968A 1967-10-04 1968-09-30 Dehydroepiandrosterone esters Expired GB1246639A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DESC041382 1967-10-04

Publications (1)

Publication Number Publication Date
GB1246639A true GB1246639A (en) 1971-09-15

Family

ID=7436199

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4629968A Expired GB1246639A (en) 1967-10-04 1968-09-30 Dehydroepiandrosterone esters

Country Status (12)

Country Link
AT (1) AT297946B (en)
BE (1) BE721825A (en)
BR (1) BR6802861D0 (en)
CS (1) CS150596B2 (en)
DK (1) DK122125B (en)
FI (1) FI45551C (en)
FR (2) FR1584879A (en)
GB (1) GB1246639A (en)
IE (1) IE32405B1 (en)
NL (1) NL160835C (en)
SE (1) SE352347B (en)
YU (1) YU33834B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2203941A (en) * 1987-04-27 1988-11-02 Daiichi Yakuhin Sangyo Kk Anti-obesity agent
GB2204490A (en) * 1987-05-06 1988-11-16 Hope City Dehydroepiandrosterone
WO1994016709A3 (en) * 1993-01-19 1994-11-24 Endorecherche Inc Therapeutic uses and delivery systems of dehydroepiandrosterone
EP0728483A1 (en) * 1993-04-16 1996-08-28 Research Development Foundation Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585124A (en) * 2019-09-26 2019-12-20 西安力邦医药科技有限责任公司 An oily injection containing estriol or its derivatives

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2203941A (en) * 1987-04-27 1988-11-02 Daiichi Yakuhin Sangyo Kk Anti-obesity agent
GB2204490A (en) * 1987-05-06 1988-11-16 Hope City Dehydroepiandrosterone
GB2204490B (en) * 1987-05-06 1991-03-27 Hope City Dehydroepiandrosterone therapy
US5854229A (en) * 1993-01-19 1998-12-29 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5922700A (en) * 1993-01-19 1999-07-13 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
CZ297860B6 (en) * 1993-01-19 2007-04-18 Endorecherche Inc. Use of sex steroid precursor for preparing pharmaceutical composition
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5780460A (en) * 1993-01-19 1998-07-14 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5798347A (en) * 1993-01-19 1998-08-25 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5807849A (en) * 1993-01-19 1998-09-15 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5824671A (en) * 1993-01-19 1998-10-20 Endorecherche Inc Therapeutic methods and delivery systems utilizing sex steroid precursors
US5837700A (en) * 1993-01-19 1998-11-17 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5843932A (en) * 1993-01-19 1998-12-01 Endorcaherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
WO1994016709A3 (en) * 1993-01-19 1994-11-24 Endorecherche Inc Therapeutic uses and delivery systems of dehydroepiandrosterone
US5872114A (en) * 1993-01-19 1999-02-16 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
EP0680327A1 (en) * 1993-01-19 1995-11-08 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5948434A (en) * 1993-01-19 1999-09-07 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5955455A (en) * 1993-01-19 1999-09-21 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
EP1382340A1 (en) * 1993-01-19 2004-01-21 Endorecherche Inc. Therapeutic uses of dehydroepiandrosterone for treating diminished libido and osteoporosis
EP0728483A1 (en) * 1993-04-16 1996-08-28 Research Development Foundation Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US6670346B1 (en) 1998-06-11 2003-12-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7429576B2 (en) 1998-06-11 2008-09-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7884092B2 (en) 1998-06-11 2011-02-08 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7943603B2 (en) 1998-06-11 2011-05-17 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8188066B2 (en) 1998-06-11 2012-05-29 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Also Published As

Publication number Publication date
AT297946B (en) 1972-03-15
SE352347B (en) 1972-12-27
DK122125B (en) 1972-01-24
DE1643046A1 (en) 1971-06-16
NL160835B (en) 1979-07-16
IE32405L (en) 1969-04-04
NL6814196A (en) 1969-04-09
DE1643046B2 (en) 1975-11-27
CS150596B2 (en) 1973-09-04
FI45551B (en) 1972-04-04
FI45551C (en) 1972-07-10
IE32405B1 (en) 1973-07-25
YU33834B (en) 1978-06-30
FR1584879A (en) 1970-01-02
BR6802861D0 (en) 1973-03-15
FR8191M (en) 1970-09-07
BE721825A (en) 1969-04-04
YU224068A (en) 1977-12-31
NL160835C (en) 1979-12-17

Similar Documents

Publication Publication Date Title
GB1246639A (en) Dehydroepiandrosterone esters
Van Heuverswyn et al. Mammary Growth in Male Mice Receiving Androgens, Estrogens and Desoxycorticosterone Acetate.
Menkin Further Studies on Effect of Adrenal Cortex Extract and of Various Steroids on Capillary Permeability.
FI67298B (en) FRAMEWORK FOR THERAPEUTIC AVERAGE THERAPEUTIC REQUIREMENT FOR STEROID
Anderson et al. Comparative pulmonary surfactant-inducing effect of three corticosteroids in the near-term rat
FELDMAN et al. Effect of prolonged use of estrogens on circulating lipids in patients with idiopathic hyperlipemia or idiopathic hypercholesteremia
US4076811A (en) Novel agents and methods for treatment of climacteric disturbances
Goodman et al. Hepatocellular carcinoma in association with androgen therapy
van den Hoogenband et al. PUVA therapy in the treatment of skin lesions of the hypereosinophilic syndrome
Lyster et al. Ability of some progestational steroids to stimulate male accessory glands of reproduction in the rat
ASADA et al. Effect of ovariectomy on serum lipid peroxide levels in women
Haleblian Bioassays used in development of topical dosage forms
Opsahl et al. Chorionic gonadotrophin, ACTH, and the adrenal-hyaluronidase relationship
GB1193464A (en) Steroidal Esters, Processes for Making them, and Therapeutic Compositions Containing them
GRAHAM et al. The influence of adrenal cortical hormones on sensitivity of mice to ionizing radiation
GB1483650A (en) Pharmaceutical preparations based on mesterolone
Hall Clinical experiences with the sublingual administration of alpha estradiol
FRANK et al. HYDROCORTISONE (COMPOUND F) FREE ALCOHOL AND HYDROCORTISONE ACETATE FOR TOPICAL USE: A Clinical Evaluation
Huggins et al. Lactation induced by luteotrophin in women with mammary cancer. Growth of the breast of the human male following estrogenic treatment
GB1505879A (en) Acylated orgotein
Heimann et al. EFFECTS OF PLASMOQUIN, ATEBRIN, AND QUININE ON THE ELECTROCARDIOGRAM
US3754086A (en) Stable oily preparations of epithio-steroids
Lipschütz et al. Comparative Conjunctive Tumorigenic Action of Three Different Esters of Estradiol.
Selye Changes in Adrenal Medulla Following Treatment with an AGTH-Preparation Containing Carboxymethylcellulose.
GB1472086A (en) Pharmaceutical composition for treatment of liver diseases